Recent research released new insights into neurotoxicity associated with CAR‑T cell therapies. The work maps clinical patterns and potential biological pathways underpinning neurological adverse events, informing monitoring strategies and mitigation approaches used by treatment centers. Authors and institutions involved in the study focused on characterizing onset timing, symptom clusters, and putative molecular mediators. The findings are likely to influence trial protocols, toxicity grading, and supportive care pathways across academic and commercial CAR‑T programs.